Abstract
Hepatocellular carcinoma (HCC) is one of the most malignant cancers, with the second highest cancer death rate world-wide, next to lung cancer. The signaling mechanisms in HCC are currently not clear. Notch signaling, which is highly conserved and plays a critical role in many cancers, was found to be aberrantly upregulated in HCC tissues compared to normal liver tissues. Accumulating evidence supports that Notch signaling plays a significantly important role in HCC carcinogenesis. This review discusses the functions of Notch signaling in HCC and its potential therapeutic applications against this cancer.
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Hepatocellular / metabolism*
-
Carcinoma, Hepatocellular / therapy
-
Combined Modality Therapy
-
Doxorubicin / therapeutic use
-
Gene Knockdown Techniques
-
Genetic Therapy
-
Humans
-
Liver Neoplasms / metabolism*
-
Liver Neoplasms / therapy
-
Molecular Targeted Therapy
-
Niacinamide / analogs & derivatives
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / therapeutic use
-
Receptors, Notch / genetics
-
Receptors, Notch / metabolism*
-
Signal Transduction
-
Sorafenib
-
Valproic Acid / therapeutic use
Substances
-
Antineoplastic Agents
-
Phenylurea Compounds
-
Receptors, Notch
-
Niacinamide
-
Valproic Acid
-
Doxorubicin
-
Sorafenib